INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY *of* WASHINGTON

Meeting Minutes

Date: Wednesday, April 16, 2025
Time: 10:00 a.m. – 12:00 p.m.

Location: Zoom

Members Present:

1. Jason Cantera *(Community Member)*
2. Lesley Colby, Comparative Medicine *(Animal Containment Expert)*
3. Lesley Decker, Environmental Health & Safety (*Biosafety Officer*)
4. Erin Heiniger, Department of Bioengineering *(Laboratory Specialist*)
5. Richard Grant, Washington National Primate Research Center
6. Jennifer Iwamoto, Office of Animal Welfare *(Animal Containment Expert)*
7. David Koelle, Allergy and Infectious Diseases
8. Stephen Libby, Laboratory Medicine *(Animal Containment Expert)*
9. Scott Meschke, Environmental & Occupational Health Sciences
10. Susan Parazzoli *(Community Member)*
11. Jason Smith, Microbiology (*IBC Chair*)
12. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)
13. Jennifer Nemhauser, Plant Expert

Commonly Used Abbreviations
AAV: adeno-associated viral vector
BSL: biosafety level
BSL-2w/3: BSL-2 with BSL-3 practices
BSO: biosafety officer
BUA: Biological Use Authorization
DURC: Dual Use Research of Concern
IACUC: Institutional Animal Care and Use Committee
IBC: Institutional Biosafety Committee
iPSCs: induced pluripotent stem cells
NHP: non-human primate
NIH: National Institutes of Health
PEPP: Pathogen with Enhanced Pandemic Potential
PI: Principal Investigator
rDNA: recombinant or synthetic DNA/RNA
RG: Risk Group
SOP: standard operating procedure
Source material: blood, tissue, body fluids, and cell lines

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:01 a.m. A quorum was present.

2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship. The IBC chair shared the new NIH requirements regarding publishing of IBC minutes and IBC member information with the committee.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the March 19, 2025, meeting.
   - A member made a motion to approve the March 19, 2025, meeting minutes. Another member seconded the motion.
   - The committee voted unanimously to approve the March 19, 2025, meeting minutes, with one abstention.

4. **OLD BUSINESS:**
   - At the March 19, 2025 meeting, Dr. Disteche's BUA was approved pending successful completion of the lab inspection. This BUA has been sent.
   - At the March 19, 2025 meeting, Dr. Escobar's BUA was approved pending submission and review of the IACUC protocol. This BUA is still pending.
   - At the March 19, 2025 meeting, Dr. Greenberg's BUA was approved pending addition of BUA letter comment stating that lab members must know what antibiotic-resistant bacterial strains they are working with in case of lab exposure. This BUA has been sent.
   - At the March 19, 2025 meeting, Dr. Merz's BUA was approved pending successful completion of the lab inspection, required training, and confirmation that PI is not conferring resistance to beta lactams in Neisseria. This BUA has been sent.
   - At the March 19, 2025 meeting, Dr. Nahmani's BUA was approved pending successful completion of the lab inspection. This BUA has been sent.
   - At the March 19, 2025 meeting, Dr. Sancak's BUA was approved pending confirmation that only AAV in mice is being added to the project. This BUA has been sent.
   - At the March 19, 2025 meeting, Dr. Soden's BUA was approved pending successful completion of the lab inspection. The BUA has not been sent.
   - At the March 19, 2025 meeting, Dr. Stevens's BUA was approved pending successful completion of the lab inspection. This BUA is still pending.
   - At the March 19, 2025 meeting, Dr. Van Voorhis's BUA was approved pending submission and review of the IACUC protocol. This BUA is still pending.

5. **BIOSAFETY OFFICER (BSO) REPORT***:* The Biosafety Officer Report includes projects involving: (1) recombinant or synthetic nucleic acids covered under Sections III-E and III-F of the *NIH Guidelines,* (2) non-recombinant biological agents requiring BSL-2 with BSL-3 practices containment or lower, and (3) administrative updates, such as room additions.
   a. Biosafety Officer Report
      - Dr. Smith added work with human stem cells in vitro and in vivo that are BBP and LCMV-free at ABSL-1 on the BUA *Viral Neuronal Tracing in Rodents with Spinal Cord Injury.*

- Dr. Phillips registered work with new non-oncogenic inserts for use with previously approved vectors on the BUA *Phasic Dopamine Release during Motivated Behavior in Rats.*
- Dr. Guo added new lab space and the use of S. aureus on the BUA *Chromosome organization in microbes.*
- Dr. Crispe initiated work with rDNA and human source material in vitro on the BUA *Crosstalk between metastatic colorectal cancer cells and their stroma.* (Section III-F)
- Dr. Prabha added new lab spaces for previously approved in vitro work on the BUA *Targeting Solid Tumors Using Nano-Engineered MSCs.*
- Dr. Barria registered work with rat cells in vitro on the BUA *Regulation of Glutamatergic Synapses.*
- Dr. Arce-McShane renewed work with non-human primates outside the primate center on the BUA *Sensorimotor Control and Learning.*
- Dr. O'Connor took over work previously overseen by Dr. Fuller on the BUA *Emerging infectious diseases and SIV co-infections.*
- Dr. Pasupathy added additional rooms for use with previously approved agents on the BUA *2-photon imaging in awake monkey visual cortex.*
- Dr. Muczynski renewed work with Epstein-Barr virus, rDNA and human source material on the BUA *Kidney Immunological Research.* (Section III-F)
- Dr. Sweet renewed work with human source material on the BUA *Islet Cell and Functional Analysis Core of Diabetes Endocrinology Research Center.*
- Dr. Goss updated rooms for work with previously approved agents on the BUA *A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Participants and Multiple-Ascending Doses and Proof-of-Concept in Participants with Cystic Fibrosis.*
- Dr. Buckner added work with wild-type M. bovis BCG on the BUA *Buckner antiparasitic and antibacterial drug discovery.*
- Dr. Hanson renewed work with human source material on the BUA *Alzheimer's Lipid Metabolism lab.*
- Dr. Barker-Haliski renewed work with Theiler's murine encephalomyelitis (TMEV) in mice and in vitro, and rDNA in vitro on the BUA *Evaluating the anticonvulsant and disease modifying potential of investigational anticonvulsant drugs in a mouse model of infection-induced seizures.* (Section III-F)
- Dr. Bruce renewed work with Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella Typhimurium and human source material the BUA *Mapping Protein-Protein Interaction Network In Human Serum, Sputum, Cancer Cells, and Bacterial Cells.*
- Dr. Paik added work with Blautia producta and Blautia wexlerae in mice on the BUA *GNAC facility.*
- The IBC Chair a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report.

6. BSL-3 INACTIVATION REPORT

- Dr. Sherman requested approval for filter sterilization (0.45µm followed by 0.2 µm filter) of Mycobacterium tuberculosis.

- The subcommittee reviewed the procedures and inactivation data provided by the lab and approved their requests.
- The IBC Chair made a motion to approve this month's BSL-3 Inactivation Report.
- The committee voted to approve this month's BSL-3 Inactivation Report.

7. DURC REPORT

- The Institutional Review Entity (IRE) reviewed Dr. West's research involving Burkholderia pseudomallei and Francisella tularensis. Attenuated mutants of Burkholderia pseudomallei obtained from collaborators are used. The project does not meet the DURC definition and a risk mitigation plan is not needed.
- The IBC Chair sought a motion to approve this month's DURC Report.
- A member made a motion to approve this month's DURC Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's DURC Report.

8. DURC-PEPP DOCUMENTS

- The EH&S Biosafety Manager presented on DURC-PEPP documents to support the upcoming policy on May 6. The documents reviewed include a new DURC-PEPP Application, Self-Assessment Worksheet, IRE Review Flow Chart, and IRE Assessment Form.
- The IBC Chair sought a motion to approve the DURC-PEPP documents.
- A member made a motion to approve the updates to DURC-PEPP documents. Another member seconded the motion.
- The Committee unanimously voted to approve the updates to DURC-PEPP documents.

9. UPDATES TO BUA APPLICATION

- The EH&S Biosafety Manager shared updates to the BUA application, BUA change application, and PI Change application, including adding questions relevant to DURC-PEPP and prion-like proteins.
- The IBC Chair sought a motion to approve updates to the BUA Application.
- A member made a motion to approve the updates to the BUA Application. Another member seconded the motion.
- The Committee unanimously voted to approve the updates to the BUA Application.

10. INDIVIDUAL PROJECT REVIEWS

a. Adams Waldorf, Kristina, new, *Nonhuman primate model of congenital toxoplasmosis*

- NIH Guidelines Sections III-D and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Adams Waldorf lab aims to develop a nonhuman primate model of Toxoplasma gondii infection in pregnancy.
- The lab works with Toxoplasma gondii in vitro and in NHPs, human source material and NHP source material at BSL-2 and rDNA at BSL-1.
- A lab inspection was not required as the lab was recently inspected.
- All required trainings are complete.
- There are occupational health recommendations for work with Toxoplasma gondii.
- This project has an IACUC protocol in review.
- The draft BUA letter was shown.

- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Adams Waldorf.
- The Committee voted unanimously to approve the draft BUA for Dr. Adams Waldorf.

b. Carr, Rotonya, renewal, *The Pathogenesis of Insulin Resistance in Alcohol-associated and Metabolic Dysfunction-associated Steatotic Liver Disease*

- NIH Guidelines Sections III-D, III-E, and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Carr lab studies steatotic liver disease by working with genes associated with lipid metabolism and regulating them using siRNA.
- The lab works with NHP and human source material in vitro at BSL-2 and AAV and rDNA at BSL-1.
- The lab was inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Carr.
- The Committee voted unanimously to approve the draft BUA for Dr. Carr.

c. Chavkin, Charles, renewal, *Chavkin-Mice*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Chavkin lab aims to understand the molecular basis of addictive drug action and to develop strategies to treat drug addiction, mood disorders, and pain.
- The lab works with human source material in vitro at BSL-2 and AAV in mice and rDNA in vitro at BSL-1.
- A lab inspection has been performed and is still pending a response.
- All required trainings are complete.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Chavkin.
- The Committee voted unanimously to approve the draft BUA for Dr. Chavkin, pending successful completion of the lab inspection and submission and review of the IACUC protocol.

d. Fuller, Deborah Lynn, renewal, *Nucleic Acid Mediated Protein Expression*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Fuller lab researches nucleic acid vaccines that encode antigens, with the goal of protein production in vivo to stimulate immune response.
- The lab works with primate lentivirus in vitro at BSL-2w/3 practices, Plasmodium berghei, Plasmodium cynomolgi, Plasmodium knowlesi in vitro and in NHPs at ABSL-2, and rDNA including enhanced gene delivery methods at BSL-1.
- The lab inspection is scheduled for after the IBC meeting.
- All required trainings are complete.
- There are occupational health requirements for work with RG2 Plasmodium species.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.

- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Fuller.
- The Committee voted unanimously to approve the draft BUA for Dr. Fuller, pending successful completion of the lab inspection and submission and review of the IACUC protocol.

e. Giachelli, Cecilia, renewal, *Vascular Calcification*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Giachelli lab investigates the formation of and potential treatments for vascular calcifications.
- The lab works with gammaretroviral vectors, human and non-human primate source material, and third generation lentiviral vectors with oncogenic inserts in vitro at BSL-2. They also use ecotropic gammaretroviral vectors and third generation lentiviral vectors in vitro at BSL-1. The lab uses multiple human iPSCs created by vendors.
- A lab inspection has been performed and is still pending a response.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Giachelli.
- The Committee voted unanimously to approve the draft BUA for Dr. Giachelli, pending successful completion of the lab inspection.

f. Jain, Aakanksha, new, *Neuronal regulation of tissue immunity*

- NIH Guidelines Sections III-D
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Jain lab studies how sensory neurons influence immune responses.
- The lab works with AAV in mice at ABSL-1.
- A lab inspection was not required as all work takes place inside a vivarium.
- All required trainings are complete.
- There are occupational health requirements for work with diphtheria toxin.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Jain.
- The Committee voted unanimously to approve the draft BUA for Dr. Jain, pending submission and review of the IACUC protocol.

g. Kennedy, Scott, change, *Somatic mutagenesis in aging and diseases*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Kennedy lab is adding work with third generation lentiviral vectors with oncogenic inserts at BSL-2, and E. coli K-12 and rDNA with enhanced gene delivery methods at BSL-1.
- The lab was inspected, and no deficiencies were noted.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kennedy.
- The Committee voted unanimously to approve the draft BUA for Dr. Kennedy, with one abstention.

h. Kiem, Hans-Peter, new, *In Vivo Gene Therapy*

- NIH Guidelines Sections III-D
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Kiem lab researches how to overcome the challenges of ex vivo stem cell gene therapy by developing methods to complete the treatment inside a patient's body.
- The lab works with lentiviral vectors, NHP source material, and rDNA with enhanced gene delivery methods in NHPs at ABSL-2.
- A lab inspection was not required as all work takes place inside a vivarium.
- All required trainings are complete.
- This project has an IACUC protocol in review.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kiem.
- The Committee voted unanimously to approve the draft BUA for Dr. Kiem.

i. Kwon, Young, renewal, *Regulation of growth and wasting*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Kwon lab studies how organ growth and wasting are regulated using Drosophila genetics and biochemistry.
- The lab works with human source material and lentiviral vectors at BSL-2, and transgenic Drosophila, E. coli, and rDNA at BSL-1.
- A lab inspection has been performed and is still pending a response.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kwon.
- The Committee voted unanimously to approve the draft BUA for Dr. Kwon, pending successful completion of the lab inspection.

j. Moreno, Claudia, renewal, *Mechanisms of Aging*

- NIH Guidelines Sections III-D and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Moreno lab studies aging.
- The lab works with human source material in vitro at BSL-2 and AAV in mice, E. coli and rDNA in vitro at BSL-1.
- The lab was inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Moreno.
- The Committee voted unanimously to approve the draft BUA for Dr. Moreno pending submission and review of the IACUC protocol.

k. Murphy, Sean, renewal, *Immunity to malaria infection*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Murphy lab aims to develop effective vaccines against malaria and other complex pathogens.

- The lab works with human and NHP source material, RG2 Plasmodium falciparum, knowlesi, and vivax in vitro, in mice, and in mosquitoes at BSL-2. They also work with RG1 Plasmodium yoelli and berghei in vitro, in mice, and in mosquitos at BSL-1.
- There are occupational health requirements for work with Plasmodium species.
- The lab was inspected, and no deficiencies were noted.
- All required trainings are complete.
- This project has an IACUC protocol in review.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Murphy.
- The Committee voted unanimously to approve the draft BUA for Dr. Murphy.

l. Odom, Guy, renewal, *Cardiopulmonary gene therapy for muscular dystrophy*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Odom lab researches treatment or cure for muscular dystrophy by delivering therapeutic genes to muscles through the bloodstream.
- The lab works with cloning strains of E. coli, AAV, murine cells, foamy viral vectors, third generation lentiviral vectors, and AAV in mice at BSL-1. They also work with human cell lines at BSL-2.
- A lab inspection has been performed and is still pending a response.
- All required trainings are complete.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Odom.
- The Committee voted unanimously to approve the draft BUA for Dr. Odom, pending successful completion of the lab inspection and pending submission and review of the IACUC protocol.

m. Rajakovich, Lauren, renewal, *Discovery and characterization of enzymes and metabolism in microbiomes*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.
- The Rajakovich lab studies metabolic pathways and enzymes from host-associated and free-living microbes that allow them to adapt and influence their environment.
- The lab works with recombinant Clostridioides difficile and various RG2 wildtype organisms at BSL-2. They also work with rDNA, lab strains of E.coli, and many wildtype RG1 that are known human gut flora organisms at BSL-1.
- The lab was inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Rajakovich.
- The Committee voted unanimously to approve the draft BUA for Dr. Rajakovich.

n. Zheng, Ning, renewal, *Protein Structural Biology - Dr. Ning Zheng Lab*

- NIH Guidelines Sections III-D, III-E and III-F
- The assigned IBC Primary Reviewer presented the Primary Review.

- The Zheng lab studies how various proteins function and how interactions among proteins relate to health.
- The lab works with third generation lentiviral vectors with oncogenic inserts and human source material at BSL-2. They work with two species of transgenic plants (Arabidopsis thaliana and Nicotiana benthamania), and use recombinant Agrobacterium tumefaciens in plants at BL1-P.
- The lab was inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Zheng.
- The Committee voted unanimously to approve the draft BUA for Dr. Zheng.

11. SUBCOMMITTEE REPORTS:

o. Nakamura, Kenta, new, *Endocardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment: A 26-Week (with 26 Week Extension) Phase 2b Randomized, Multi-Center, Double-Blind, Sham Controlled Study to Evaluate Efficacy and Safety*

- NIH Guidelines Sections III-C
- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is an industry-sponsored, multi-site, non-first-in-humans study designed to reduce angina and objective ischemia.
- An adenoviral vector-based gene therapy product are administered to human study participants.
- All required trainings are complete.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Nakamura. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Nakamura.

p. Portuguese, Andrew, new, *A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma*

- NIH Guidelines Sections III-C
- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is an industry-sponsored, multi-site, non-first-in-humans study designed to determine effectiveness on relapsed/refractory multiple myeloma.
- Human cells transduced with third generation lentiviral vectors are administered to human study participants.
- All required trainings are complete.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Portuguese. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Portuguese.

q. Specht, Jennifer (004), new, *A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod CAR T, in Heterozygous HLA-A*02 Adults with*

*Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression.*

- NIH Guidelines Sections III-C
- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is an industry-sponsored, multi-site, non-first-in-humans study designed to treat recurrent, unresectable, locally advanced, or metastatic solid tumors.
- Human cells transduced with third generation lentiviral vectors are administered to human study participants.
- All required trainings are complete.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Specht. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Specht.

r. Specht, Jennifer (005), new, *A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Combination of CLBR001, an Engineered Autologous T Cell Product, and ABBV-461, an Antibody-Based Biologic, in Subjects with Locally Advanced or Metastatic Breast Cancer*

- NIH Guidelines Sections III-C
- Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- This is an industry-sponsored, multi-site, non-first-in-humans study designed to determine tolerability and effectiveness of CLBR001 and ABBV-461 in participants with locally advanced or metastatic breast cancer.
- Human cells transduced with third generation lentiviral vectors are administered to human study participants.
- All required trainings are complete.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. Specht. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. Specht.

s. West, T. Eoin, renewal, *Host genetics and response to infection*

- NIH Guidelines NIH Guidelines Sections III-D, III-E, and III-F
- Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
- The West lab studies how genetic variations and other host elements alter response to infections in the lung.
- The lab works with Burkholderia pseudomallei and Francisella tularensis in vitro and in mice at BSL-3. They use Burkholderia thailandensis, Francisella novicida, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae in mice at BSL-2, and mouse cells transduced with lentiviral vectors in mice at BSL-1.
- BSL-3 labs are inspected quarterly and not in association with BUAs/projects.
- The BSL-1 and BSL-2 labs were inspected, and all deficiencies have been corrected.
- All required trainings are complete.
- There are occupational health requirements for work with Streptococcus pneumoniae.

- Medical management plans are in place for Burkholderia pseudomallei and Francisella tularensis.
- The IACUC protocol is still pending.
- The draft BUA letter was shown.
- A member made a motion to approve the draft BUA letter for Dr. West. Another member seconded the motion.
- The Committee voted unanimously to approve the draft BUA for Dr. West, pending submission and review of the IACUC protocol.

10. FOR YOUR INFORMATION:

- EH&S checked in with IBC to query for any feedback on the current state of lab funding and operations and ways to provide support.

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS: There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 12:01pm